The longevity medicine conversation is often implicitly aimed at adults in their 30s to 50s — people investing in a future they can meaningfully shape. But a large fraction of the audience for longevity science is already in their 60s, 70s, and 80s — seeking not to reverse decades of choices but to make the most of the biology they have. The evidence for maintaining and improving health, cognition, and function in the later decades is compelling and genuinely encouraging.
The discourse around longevity medicine carries an implicit assumption that its audience is primarily young and middle-aged — that the most meaningful investment is in prevention decades before disease manifests. This framing is correct but incomplete. Adults in their 70s and 80s have a different but equally important longevity opportunity: optimizing function, independence, and healthspan in the years they have, and slowing the functional decline that transitions healthy old age into dependent old age. The evidence for meaningful intervention in the later decades is both more robust and more encouraging than is commonly understood.1
Sarcopenia — the progressive loss of skeletal muscle mass and strength with aging — is the most powerful predictor of functional decline and mortality in older adults that is directly modifiable. It predicts falls and fractures (muscle weakness is the primary cause of falls), hospitalization rates, recovery time from illness and surgery, functional independence (the ability to live independently), and all-cause mortality. The good news: skeletal muscle is extraordinarily responsive to resistance training stimulus even in very old adults. Multiple RCTs have demonstrated significant increases in muscle mass, strength, and functional performance from resistance training in adults over 80, including those with frailty.2
The minimum effective dose for sarcopenia prevention and reversal: 2 to 3 sessions per week of progressive resistance exercise targeting major muscle groups, with loads at 60 to 80 percent of one-repetition maximum (or, for those who cannot safely perform loaded exercises, high-repetition lower-load training to fatigue). Protein intake must be co-optimized — resistance training without adequate protein (35 to 40 grams per meal, 3 meals per day) produces substantially less muscle mass gain in older adults than the combination. The LIFTMOR trial established that even high-intensity resistance training is safe and effective in older adults with osteopenia, when supervised appropriately.
Polypharmacy — defined as the simultaneous use of 5 or more medications — affects over 40 percent of adults over 65 and over 60 percent of adults over 75 in developed countries. Each additional medication adds the possibility of drug-drug interactions, drug-disease interactions, and cumulative adverse effects. The consequences are often misattributed to aging rather than medication: cognitive impairment from anticholinergic drugs (many antihistamines, overactive bladder medications, certain antidepressants), orthostatic hypotension from antihypertensives (the leading medication-related cause of falls), sedation and falls from benzodiazepines and Z-drugs, and delirium from opioids.3
The Beers Criteria (American Geriatrics Society) identifies medications with potentially inappropriate use in older adults — a list that includes dozens of commonly prescribed medications. Annual medication review with a geriatrician, clinical pharmacist, or informed primary care physician using a deprescribing framework is one of the highest-value interventions available to older adults taking multiple medications. Reducing polypharmacy frequently improves cognition, fall risk, quality of life, and hospitalizations.
The evidence base for cardiovascular risk factor treatment requires recalibration in very old adults. Intensive blood pressure treatment (target below 120 mmHg systolic) produces significant cardiovascular event reduction in adults over 75 — the SPRINT trial subgroup analysis confirmed this — but carries higher rates of orthostatic hypotension, falls, and acute kidney injury. Statin therapy for secondary prevention (established cardiovascular disease) remains clearly beneficial in adults over 75. Primary prevention statin therapy in adults over 80 without established cardiovascular disease is less well-supported. These are individualized decisions requiring consideration of functional status, life expectancy, and treatment burden.4
Cognitive reserve — the brain's resilience against the effects of Alzheimer's pathology and age-related neurodegeneration — is built across a lifetime through education, intellectual engagement, bilingualism, social connection, and physical activity. People with high cognitive reserve can tolerate substantially higher amounts of Alzheimer's pathology before showing clinical symptoms — meaning that the brain investments of a lifetime delay the onset of dementia even as neuropathology accumulates. For older adults, the activities that build ongoing cognitive reserve include: learning new complex skills (musical instruments, second languages, complex crafts), social engagement that requires active cognitive processing, and physical exercise (which continues to produce BDNF and neurogenesis at any age).5
